Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 BS
Drug: Ritonavir
Drug: TRUVADA

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 33

Registration Number: NCT02253901

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BEA 2180 BR
Drug: Placebo
Device: Respimat®

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 59

Registration Number: NCT02254122

Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BILR 355 - Treatment D (current tablet formulation)
Drug: BILR 355 - Treatment A (current tablet formulation)
Drug: BILR 355 - Treatment B (new tablet formulation)
Drug: BILR 355 - Treatment E (new capsule formulation)
Drug: BILR 355 - Treatment C (new capsule formulation)
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02253940

Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Carbamazepine
Drug: Tipranavir
Drug: Ritonavir

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 28

Registration Number: NCT02253849

Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir (TPV)
Drug: Ritonavir
Drug: Omeprazole

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT02253875

Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: TPV - Refrigerated conditions
Drug: TPV - Room condition
Drug: Ritonavir (RTV)

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02253888

Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Matching placebo
Drug: BI 1181181 Healthy young
Drug: BI 1181181 healthy elderly

First Posted Date: 2014-10-01

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02254161

Locations: 🇩🇪
1344.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Serevent® Diskus®
Drug: Spiriva®
Drug: Tiotropium/Salmeterol

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02254174

Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: EFV
Drug: TPV/RTV - high dose
Drug: TPV/RTV - low dose

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 68

Registration Number: NCT02253823

Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBT 986 BS

First Posted Date: 2014-10-01

Last Posted Date: 2014-10-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 23

Registration Number: NCT02254070

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy